Since then, IN administration of insulin aqueous solutions has been extensively studied in various preclinical and clinical trials for the treatment of Alzheimer’s disease, mild cognitive impairment, diabetes, insulin resistance, and Parkinson’s disease, among other conditions. This evidence concerns the gene INS and Alzheimer disease.